An Open-label Study With Maintenance Dosing of ORKA-002 in Participants With Moderate-to-Severe Plaque Psoriasis

ClinicalTrials.gov ID: NCT07933783

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07933783. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 7:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label Study With Maintenance Dosing to Evaluate the Long-term Safety, Tolerability, and Efficacy of ORKA-002 in Participants With Moderate-to-Severe Plaque Psoriasis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

An open-label study with maintenance dosing to evaluate the long-term safety and efficacy of ORKA-002 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.

Study identification

NCT ID: NCT07933783
Recruitment status: Enrolling by invitation
Study type: Interventional
Phase: Phase 2
Lead sponsor: Oruka Therapeutics, Inc.; Industry
Enrollment: 160 participants

Conditions and interventions

Conditions

Plaque Psoriasis

Interventions

ORKA-002 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 79 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 26, 2026 (Actual)
Primary completion: Jul 1, 2029 (Estimated)
Completion: Sep 1, 2029 (Estimated)
Last update posted: Nov 12, 2026

2026 – 2029

United States locations

U.S. sites: 5
U.S. states: 5
U.S. cities: 5

Facility	City	State	ZIP	Site status
Oruka Therapeutics Investigative Site	Fountain Valley	California	92708	—
Oruka Therapeutics Investigative Site	Milford	Massachusetts	01757	—
Oruka Therapeutics Investigative Site	New Brighton	Minnesota	55112	—
Oruka Therapeutics Investigative Site	Wilmington	North Carolina	28405	—
Oruka Therapeutics Investigative Site	Warrenton	Oregon	97146	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07933783, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 12, 2026 · Synced Nov 13, 2026